A holistic approach to androgen deprivation therapy: Treating the cancer without hurting the patient

Urologia Internationalis

Volumn 83, Issue 4, 2009, Pages 373-378

  Tombal, Bertrand ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Androgen deprivation therapy; Prevention; Prostate cancer; Quality of life; Side effects

Indexed keywords

ADIPONECTIN; ALENDRONIC ACID; ANTIANDROGEN; CALCIUM; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; COLECALCIFEROL; CYPROTERONE ACETATE; DENOSUMAB; DIETHYLSTILBESTROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PROSTAGLANDIN; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

ACUPUNCTURE; ADVANCED CANCER; ALCOHOL CONSUMPTION; ANDROGEN DEPRIVATION THERAPY; ANEMIA; BODY FAT; BONE DENSITY; BREAST CANCER; CARDIOTOXICITY; COGNITIVE DEFECT; DEPRESSION; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; FOOD INTAKE; FRAGILITY FRACTURE; GYNECOMASTIA; HEART DEATH; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HOLISTIC CARE; HOT FLUSH; HUMAN; IMPOTENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LOW DRUG DOSE; LOW FAT DIET; MENTAL INSTABILITY; MUSCLE ATROPHY; MUSCLE EXERCISE; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PROSTATE CANCER; PSYCHOLOGICAL WELL BEING; REVIEW; SALVIA; SEXUAL DYSFUNCTION; SMOKING CESSATION; SOYBEAN; SUDDEN DEATH; SYSTEMATIC REVIEW; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT BEARING;

ANDROGEN ANTAGONISTS; HOLISTIC HEALTH; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 72049107165     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000251174     Document Type: Review

References (35)

1. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F: EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
2. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL: Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-181.
3. Gomella LG: Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int 2007; 99(suppl 1):25-29.
4. Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U: Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 2006; 98: 20-27.
5. Holzbeierlein JM: Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am 2006; 33: 181-190.
6. Schow DA, Renfer LG, Rozanski TA, Thompson IM: Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998; 91: 855-857.
7. Moyad MA: Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol 2005; 23: 56-64.
8. Barton D, LaVasseur B, Sloan JA, Stella PJ, Flynn K, Dyar M, Dakhil SR, Atherton PJ, Diekmann B, Loprinzi CL: A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9 (abstract 9538). J Clin Oncol 2008; 26(suppl):511.
9. Loprinzi CL, Sloan JA, Stearns V, Diekmann B, Novotny PJ, Kimmick G, Gordon P, Pandya KJ, Guttuso T, Reddy S: Newer antidepressants and gabapentin for hot flashes: an individual subject pooled analysis (abstract 9537). J Clin Oncol 2008; 26(suppl):510.
10. Irani J, Mottet N, Salomon L, Oba R, Bouchard P: Randomized, double blind study comparing efficacy and tolerance of venlafaxine (Effexor - ) vs. medroxyprogesterone acetate (Gestoral - ) vs. cyproterone acetate (Androcur - ) for vasomotor hot flashes in men on GnRH-analogs for prostate cancer (abstract 42). Eur Urol Suppl 2009; 8: 131.
11. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD, Stanford JL: Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002; 94: 430-437.
12. Aucoin MW, Wassersug RJ: The sexuality and social performance of androgen-deprived (castrated) men throughout history: implications for modern day cancer patients. Soc Sci Med 2006; 63: 3162-3173.
13. Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G: Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol 2005; 23: 3830-3842.
14. Demark-Wahnefried W, Clipp EC, Lipkus IM, Lobach D, Snyder DC, Sloane R, Peterson B, Macri JM, Rock CL, McBride CM, Kraus WE: Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. J Clin Oncol 2007; 25: 2709-2718.
15. Higano CS: Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003; 61(suppl 1):32-38.
16. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164.
17. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL: Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-7903.
18. Suominen H: Muscle training for bone strength. Aging Clin Exp Res 2006; 18: 85-93.
19. Benton MJ, White A: Osteoporosis: recommendations for resistance exercise and supplementation with calcium and vitamin D to promote bone health. J Community Health Nurs 2006; 23: 201-211.
20. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A: Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370: 657-666.
21. Ebeling PR: Clinical practice. Osteoporosis in men. N Engl J Med 2008; 358: 1474-1482.
22. Tinetti ME: Clinical practice. Preventing falls in elderly persons. N Engl J Med 2003; 348: 42-49.
23. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR: Osteoporosis in men with prostate carcinoma receiving androgendeprivation therapy: recommendations for diagnosis and therapies. Cancer 2004; 100: 892-899.
24. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-755.
25. Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R: Changes in muscle, fat and bone mass after weeks of maximal androgen blockade for prostate cancer. BJU Int 2008; 102: 44-47.
26. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-3983. (Pubitemid 46630747)
27. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS: Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112: 2188-2194.
28. Smith MR, Lee H, Nathan DM: Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-1308.
29. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456.
30. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS: Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493-1500.
31. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516-1524.
32. Galvão DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU: Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 2006; 38: 2045-2052.
33. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA: Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003; 21: 1653-1659.
34. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D'Angelo ME: Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009; 27: 344-351.
35. Schulman C: Assessing the attitudes to prostate cancer treatment among European male patients. BJU Int 2007; 100(suppl 1):6-11